TY - JOUR

T1 - The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response

T2 - Results From the NeuroPharm 1 Study

AU - Larsen, Soren Vinther

AU - Ozenne, Brice

AU - Kohler-Forsberg, Kristin

AU - Poulsen, Asbjorn Seenithamby

AU - Dam, Vibeke Hoyrup

AU - Svarer, Claus

AU - Knudsen, Gitte Moos

AU - Jorgensen, Martin Balslev

AU - Frokjaer, Vibe Gedso

PY - 2022

Y1 - 2022

N2 - BackgroundHormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC's effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive (OC) users relative to non-users have lower cerebral serotonin 4 receptor (5-HT4R) levels. Here, we determine if cerebral 5-HT4R binding differs between HC non-users, OC users, and hormonal intrauterine device (HIUD) users among women with an untreated depressive episode. Also, we test if antidepressant drug treatment response and its association with pre-treatment 5-HT4R binding depends on HC status. Methods[C-11]-SB207145 Positron Emission Tomography imaging data from the NeuroPharm-NP1 Study (NCT02869035) were available from 59 depressed premenopausal women, of which 26 used OCs and 10 used HIUDs. The participants were treated with escitalopram. Treatment response was measured as the relative change in the Hamilton Depression Rating Scale 6 items (r Delta HAMD(6)) from baseline to week eight. Latent variable models were used to evaluate the association between global 5-HT4R binding and OC and HIUD use as well as r Delta HAMD(6). ResultsWe found no evidence of a difference in global 5-HT4R binding between depressed HC users and non-users (p >= 0.51). A significant crossover interaction (p=0.02) was observed between non-users and OC users in the association between baseline global 5-HT4R binding and week eight r Delta HAMD(6); OC users had 3-4% lower binding compared to non-users for every 10% percent less improvement in HAMD(6). Within the groups, we observed a trend towards a positive association in non-users (p(adj)=0.10) and a negative association in OC users (p(adj)=0.07). We found no strong evidence of a difference in treatment response between the groups (p=0.13). ConclusionsWe found no difference in 5-HT4R binding between HC users vs. non-users in depressed women, however, it seemed that 5-HT4R settings differed qualitatively in their relation to antidepressant drug treatment response between OC users and non-users. From this we speculate that depressed OC users constitutes a special serotonin subtype of depression, which might have implications for antidepressant drug treatment response.

AB - BackgroundHormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC's effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive (OC) users relative to non-users have lower cerebral serotonin 4 receptor (5-HT4R) levels. Here, we determine if cerebral 5-HT4R binding differs between HC non-users, OC users, and hormonal intrauterine device (HIUD) users among women with an untreated depressive episode. Also, we test if antidepressant drug treatment response and its association with pre-treatment 5-HT4R binding depends on HC status. Methods[C-11]-SB207145 Positron Emission Tomography imaging data from the NeuroPharm-NP1 Study (NCT02869035) were available from 59 depressed premenopausal women, of which 26 used OCs and 10 used HIUDs. The participants were treated with escitalopram. Treatment response was measured as the relative change in the Hamilton Depression Rating Scale 6 items (r Delta HAMD(6)) from baseline to week eight. Latent variable models were used to evaluate the association between global 5-HT4R binding and OC and HIUD use as well as r Delta HAMD(6). ResultsWe found no evidence of a difference in global 5-HT4R binding between depressed HC users and non-users (p >= 0.51). A significant crossover interaction (p=0.02) was observed between non-users and OC users in the association between baseline global 5-HT4R binding and week eight r Delta HAMD(6); OC users had 3-4% lower binding compared to non-users for every 10% percent less improvement in HAMD(6). Within the groups, we observed a trend towards a positive association in non-users (p(adj)=0.10) and a negative association in OC users (p(adj)=0.07). We found no strong evidence of a difference in treatment response between the groups (p=0.13). ConclusionsWe found no difference in 5-HT4R binding between HC users vs. non-users in depressed women, however, it seemed that 5-HT4R settings differed qualitatively in their relation to antidepressant drug treatment response between OC users and non-users. From this we speculate that depressed OC users constitutes a special serotonin subtype of depression, which might have implications for antidepressant drug treatment response.

KW - hormonal contraception

KW - oral contraception

KW - hormonal intrauterine device

KW - [11C]SB207145

KW - serotonin

KW - major depressive disorder

KW - serotonin 4 receptor

KW - sex steroid hormones

KW - 5-HT4 RECEPTOR-BINDING

KW - HUMAN BRAIN

KW - ESTROGEN

KW - ASSOCIATION

KW - FLUOXETINE

KW - THERAPY

U2 - 10.3389/fendo.2022.799675

DO - 10.3389/fendo.2022.799675

M3 - Journal article

C2 - 35360055

VL - 13

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 799675

ER -